Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT02989025
PHASE2

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

Sponsor: University of Mississippi Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.

Official title: Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia-The PROGRESS Pilot Study

Key Details

Gender

FEMALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2017-05-22

Completion Date

2027-01-31

Last Updated

2025-07-08

Healthy Volunteers

No

Interventions

DRUG

17 OHPC

The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.

Locations (1)

Winfred L. Wiser Hospital

Jackson, Mississippi, United States